



## Evolution of Treatment and Predictive Factors in SCCHN

Guest Editor:

**Prof. Dr. Denis Soulieres**

Centre de recherche du Centre  
Hospitalier de l'Université de  
Montréal (CR-CHUM) and Institut  
du cancer de Montréal, Montréal,  
Québec, Canada

Deadline for manuscript  
submissions:  
**closed (5 June 2023)**


### Message from the Guest Editor

*Cancers* will hold a Special Issue on squamous cell carcinoma of the head and neck (SCCHN). This Special Issue is dedicated to discussing current standard practices and future perspectives in treatment and predictive factors in SCCHN. The articles included herein cover a broad range of topics, with the goal being to provide a comprehensive overview of the state-of-the-art knowledge related to SCCHN.

In this Special Issue, “Evolution of treatment and predictive factors in SCCHN”, authors are invited to contribute cutting-edge studies that will further highlight the contents of immunotherapy, targeted therapy and prognostic markers in SCCHN.

I would be honored to have you collaborate for this Special Edition. Specifically, and knowing some of your work, I would like to discuss further initiatives that are not yet published and could be included in this journal. Evidently, any work will require revisions by the standards established by the journal.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)